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We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-
VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an eﬀective
treatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common. The recent reports
may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs.
There have been several well-publicized prospective, randomized studies that demonstrated the eﬃcacy of intravitreal injection of
anti-VEGF drugs for patients with AMD. Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation,
and it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy. Intravitreal injection of
bevacizumab(IVB)resultsinasubstantialdecreaseinbleedingfromtheretinalvesselsornewvesselsduringastandardvitrectomy.
IVB has also been reported to be eﬀective for inducing the regression of new vessels in proliferative diabetic retinopathy. The use
of bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the
subsequent vitrectomy. Some authors reported cases of resolution of stage 4A ROP after bevacizumab injection.
1.Introduction
Recent clinical trials regarding the intravitreal injection of
anti-VEGF agents (ranibizumab, bevacizumab, pegaptanib,
andaﬂibercept)haveshownexcellentresultsinthetreatment
of angiogenic pathologies including choroidal neovascular-
ization [1–10], macular edema [11–18], proliferative dia-
betic retinopathy [19–23], and neovascular glaucoma (NVG)
[24–32]. Ranibizumab (Lucentis, Genentech, San Francis-
c o ) ,af r a g m e n to fah u m a n i z e dm o n o c l o n a la n t i b o d y
against all VEGF isoforms, is beneﬁcial in the treatment of
choroidal neovascularization secondary to age-related mac-
ular degeneration [1–7]. Bevacizumab (Avastin, Genentech,
San Francisco), a humanized recombinant monoclonal IgG
antibody that binds and inhibits all VEGF isoforms, has been
approved as an adjuvant agent for the treatment of colorectal
carcinoma and has also been increasingly used as an oﬀ-label
therapyintheﬁeldofophthalmology. Pegaptanib(Macugen,
P ﬁ z e r ,N e wY o r k ) ,a2 8 - b a s er i b o n u c l e i ca c i da p t a m e r ,
covalently linked to two branched 20-kD polyethylene glycol
moieties, was developed to bind and block the activity of
extracellular VEGF, speciﬁcally the 165 amino acid isoform
(VEGF165) [7]. Aﬂibercept (VEGF Trap-Eye, Regeneron,
New York; Bayer, Berlin, Germany) is a 115-kDa recombi-
nantfusionproteinconsistingoftheVEGF-bindingdomains
of human VEGF receptors 1 and 2 fused to the Fc domain of
human immunoglobulin-G1 [18].
Intravitreal injection of anti-VEGF agents has also been
reported to be eﬀective for inducing the regression of new
vessels in proliferative diabetic retinopathy (PDR) [19, 20,
33, 34] and neovascular glaucoma (NVG) [24–32, 35]a n d
for improving the vascular permeability in macular edema
[11–18]. This injection may provide suﬃcient time to treat
the PDR and NVG patients with retinal photocoagulation.
In addition, it may also be used as an adjunctive therapy
for mitomycin C (MMC) trabeculectomy to treat NVG [34–
38]. Bleeding from the retinal vessels or new vessels during
a standard vitrectomy after IVB has been reported to occur
signiﬁcantly less frequently than that observed during a2 Journal of Ophthalmology
standard vitrectomy without bevacizumab therapy [19, 33,
39–41].Petersetal.[42]reportedontheultrastructuralﬁnd-
ings in the primate eye after an IVB. They showed chorio-
capillaris endothelial fenestrations to dramatically decrease
after the injection. In a normal eye, the retinal pigment
epithelium (RPE) secretes VEGF at its basal side, which is
required for the maintenance of the choriocapillaris [43].
The absence of VEGF may cause a loss of endothelial fenes-
trations [44]. Moreover, topical, subconjunctival, or stromal
injectionsofbevacizumabagainstcornealneovascularization
were also eﬀective and well tolerated [45–47].
We herein review articles describing intravitreal injection
ofanti-VEGFdrugtrials,whilediscussingthemechanismsof
the action of anti-VEGF antibodies,and also evaluating their
outcomes.
2. Evaluations of the Outcomes of Anti-VEGF
Therapy for Macular Edema following
Retinal VeinOcclusion (RVO)
The upregulation of VEGF expression was noted to be
elevated in the ocular ﬂuids of central retinal vein occlusion
(CRVO) patients [48] and VEGF mRNA expression is also
upregulated in the inner nuclear layer in human CRVO path-
ological specimens [49]. Recent studies have demonstrated
that increased production of VEGF occurs early in the dis-
ease process and is a major contributor to macular edema
following CRVO or branch retinal vein occlusion (BRVO)
[11–13]. Thus, there is strong rationale for using VEGF
antagonists to treat macular edema following RVO.
There have been two large, well-designed (prospective,
randomized, sham injection-controlled, double-masked,
multicenter), phase III trials in patients with macular edema
following CRVO [14, 15]o rB R V O[ 16, 17].
2.1. CRUISE Study [14, 15]. In the Ranibizumab for the
TreatmentofMacularEdemaafterCentralRetinalVeinOccl-
UsIon Study: Evaluation of Eﬃcacy and Safety (CRUISE)
study, the 392 eligible patients were randomized 1:1:1
to receive 6 monthly intraocular injections of 0.3mg or
0.5mg of ranibizumab or sham injections during the 6-
month treatment period. After 6 months, all patients with
best-corrected visual acuity (BCVA) 20/40 or a central
foveal thickness (CFT) 250µmw e r ea l l o w e dt or e c e i v e
ranibizumab treatment during the 6-month treatment
period. The mean change from baseline BCVA letter score
at month 6 was 12.7 and 14.9 in the 0.3mg and 0.5mg
ranibizumab groups, respectively, and 0.8 in the sham group
(P<0.0001 for each ranibizumab group versus sham).
The percentage of patients who gained 15 letters in BCVA
at month 6 was 46.2% (0.3mg) and 47.7% (0.5mg) in
the ranibizumab groups and 16.9% in the sham group
(P<0.0001 for each ranibizumab group versus sham). At
month 6, signiﬁcantly more ranibizumab-treated patients
(0.3mg = 43.9%; 0.5mg = 46.9%) had a BCVA of 20/40
compared with sham patients (20.8%; P<0.0001 for each
ranibizumabgroupversussham),andtheCFThaddecreased
by a mean of 434µm (0.3mg) and 452µm( 0 . 5 m g )i n
the ranibizumab groups and 168µm in the sham group
(P<0.0001 for each ranibizumab group versus sham). The
median percent reduction in the excess foveal thickness at
month 6 was 94.0% and 97.3% in the 0.3mg and 0.5mg
ranibizumab groups, respectively, and 23.9% in the sham
group.
At 12 months, the mean change from the baseline BCVA
letter score was 13.9 and 13.9 in the 0.3mg and 0.5mg
ranibizumabgroups,respectively,and7.3inthesham/0.5mg
group (P<0.001 for each ranibizumab group versus
sham/0.5mg). The percentage of patients who gained 15
letters from the baseline BCVA at month 12 was 47.0%
and 50.8% in the 0.3mg and 0.5mg ranibizumab groups,
respectively, and 33.1% in the sham/0.5mg group. On
average, there was a marked reduction in the CFT after
the ﬁrst as-needed injection of 0.5 mg ranibizumab in the
sham/0.5mg group to the level of the ranibizumab groups,
which was sustained through month 12.
Intraocularinjectionsof0.3mgor0.5mgofranibizumab
provided rapid improvements in the 6-month visual acuity
and CFT following CRVO, and treatments with ranibizumab
as needed during months 6 through 11 maintained the visual
andanatomicbeneﬁtsachievedby6monthlyinjections,with
low rates of ocular and nonocular safety events. After sham
injections for 6 months, ranibizumab injections as needed
for 6 months resulted in a rapid reduction in the CFT in the
sham group to a level similar to that in the two ranibizumab
treatment groups, and an improvement in the BCVA, but
not to the same level as that in the two ranibizumab groups.
This suggests that there may be a visual penalty incurred
by delaying ranibizumab injections in patients with macular
edema following CRVO.
Intraocular injections of ranibizumab are considered
to be an eﬀective treatment for macular edema after
CRVO. However, during the observation period, recur-
rent/persistent edema or BCVA 20/40 was common,
necessitating an injection of ranibizumab approximately
two-thirds of the time in each group. Additional studies
are needed to provide longer follow-up of patients with
CRVO treated with ranibizumab to determine whether the
dependence on injections is reduced over time and whether
strategies such as scatter photocoagulation to areas of retinal
nonperfusion provide an added beneﬁt.
2.2. BRAVO Study [16, 17]. In the RanibizumaB for the
Treatment of Macular Edema after BRAnch Retinal Vein
Occlusion: Evaluation of Eﬃcacy and Safety (BRAVO) study,
397 eligible patients were randomized 1:1:1 to receive
6 monthly intraocular injections of 0.3mg or 0.5mg of
ranibizumab or sham injections during the 6-month treat-
ment period. After 6 months, all patients with best-corrected
visual acuity (BCVA) 20/40 or CFT 250µmw e r ea l l o w e d
to receive ranibizumab during the 6-month observation
period. Patients could also undergo rescue laser treatment
once during the treatment and observation period.
The mean change from the baseline BCVA letter score at
month 6 was 16.6 and 18.3 in the 0.3mg and 0.5mg rani-
bizumab groups and 7.3 in the sham group (P<0.0001Journal of Ophthalmology 3
for each ranibizumab group versus sham). The percentage
of patients who gained 15 letters in BCVA at month 6
was 55.2% (0.3mg) and 61.1% (0.5mg) in the ranibizumab
groups and 28.8% in the sham group (P<0.0001 for each
ranibizumab group versus sham). At month 6, signiﬁcantly
more ranibizumab-treated patients (0.3mg, 67.9%; 0.5mg,
64.9%) had a BCVA of 20/40 compared with sham
patients (41.7%; P<0.0001 for each ranibizumab group
versus sham); and the CFT had decreased by a mean of
337µm (0.3mg) and 345µm (0.5mg) in the ranibizumab
groups and 158µm in the sham group (P<0.0001 for
each ranibizumab group versus sham). The median percent
reduction in excess foveal thickness at month 6 was 97.0%
and 97.6% in the 0.3mg and 0.5mg ranibizumab groups
and 27.9% in the sham group. More patients in the sham
group(54.5%)receivedrescuegridlasertreatmentcompared
with the 0.3mg (18.7%) and 0.5mg (19.8%) ranibizumab
groups.
At 12 months, the mean change from the baseline
BCVA letter score was 16.4 and 18.3 in the 0.3mg and
0.5mg ranibizumab groups, respectively, and 12.1 in the
sham/0.5mg group (P<0.01, each ranibizumab group
versus sham/0.5mg). The percentage of patients who gained
15 letters from the baseline BCVA at month 12 was 56.0%
and 60.3% in the 0.3mg and 0.5mg groups, respectively,
and 43.9% in the sham/0.5mg group. On average, there was
a marked reduction in the CFT after the ﬁrst as-needed
injection of 0.5mg ranibizumab in the sham/0.5mg group,
which was sustained through month 12. No new ocular or
nonocular safety events were identiﬁed.
Intraocularinjectionsof0.3mgor0.5mgofranibizumab
provided a rapid improvement in the 6-month visual
acuity and macular edema following BRVO, and treatments
with ranibizumab as needed during months 6 through
11 maintained the visual and anatomic beneﬁts achieved
by 6 monthly injections, with low rates of ocular and
nonocular safety events. In the sham group, treatment
with ranibizumab as needed for 6 months resulted in a
rapid reduction of the CFT to a similar level as that
in the 0.3 mg ranibizumab group and an improvement
in the BCVA, but not to the extent of that in the two
ranibizumab treatment groups. This suggests that prolonged
edema resulting from undertreatment, due to either an as-
needed (PRN = pro re nata) dosing schedule or a delay
in the initiation of treatment, may result in irreversible
retinal damage. Intraocular injections of ranibizumab are
considered to be an eﬀective treatment for macular edema
after BRVO. However, at 12 months, some patients in each of
the groups had a CFT > 250µm (16.4% in the 0.3mg group,
13.7% in the 0.5mg group, and 21.2% in the sham/0.5mg
group), indicating that the resolution of edema was not
universal. Future therapies that address the vein blockage
or reduce VEGF production in the aﬀected retina may be
necessaryto reduce the need forongoing injection therapy in
many patients. Until that time, the mainstay of treatment for
macular edema following BRVO is likely to involve frequent
intraocular anti-VEGF injections with or without grid laser
photocoagulation.
3. Evaluationsof the Outcomes of Anti-VEGF
Therapy for Diabetic Macular Edema
Diabetic macular edema (DME) is the most common cause
of moderate vision loss in patients with diabetic retinopa-
thy [50–52]. The pathogenesis of DME is not completely
understood, but hyperglycemia- and hypoxia-induced VEGF
release are contributing factors [53, 54]. The injection of
VEGF into mouse eyes causes the breakdown of the inner
blood-retinal barrier [55], and sustained release of VEGF
in the eyes of monkeys causes macular edema [56]. The
intravitreal VEGF levels have been shown to be elevated in
patientswithDME[48].Thereha v ebeensev eralprospectiv e,
randomized studies that have demonstrated the eﬃcacy of
intravitreal injection of anti-VEGF drugs (ranibizumab and
aﬂibercept; VEGF Trap-Eye) for patients with DME [18, 57–
60].
3.1. The RESOLVE Study [57]. This study was a 12-month,
multicenter, sham controlled, double-masked study (age >
18 years, type 1 or 2 diabetes, central foveal thickness
(CFT) > 300µm, and BCVA of 73–39 ETDRS letters) with
eyes randomly assigned to intravitreal ranibizumab (0.3
or 0.5mg; n = 51 each) or sham (n = 49) treatment.
The treatment schedule comprised three monthly injections,
after which treatment could be stopped/reinitiated with
an opportunity for rescue laser photocoagulation. After
month 1, dose doubling was permitted (protocol-deﬁned
criteria, the injection volume increased from 0.05 to 0.1mL
and remained at 0.1mL thereafter). The eﬃcacy (BCVA
and CFT) and safety were compared between the pooled
ranibizumab and sham arms using the full analysis set
(n = 151, patients receiving 1 injection). At month
12, the mean ± SD BCVA improved from baseline by
10.3 ±9.1 letters with ranibizumab and declined by 1.4 ±
14.2 letters with sham treatment (P<0.0001). The mean
CFT reduction was 194.2 ± 135.1µm with ranibizumab and
48.4 ± 153.4µm with sham treatment (P<0.0001). A gain
of 10 letters BCVA from baseline occurred in 60.8% of
the ranibizumab and 18.4% of sham eyes (P<0.0001).
This phase II randomized multicenter study demonstrated
that ranibizumab monotherapy was well tolerated and
signiﬁcantlymoreeﬀectivethanshamtreatment(withrescue
laser) in providing rapid and continuous improvements in
the BCVA over 12 months (mean BCVA letter score change
from baseline to month 12, +10.3 for ranibizumab versus
−1.4 for sham; P<0.0001).
3.2. The RESTORE Study [58]. The RESTORE study was
a 12-month, double-masked, multicenter, laser-controlled,
phase III study where 345 eligible patients from 73 cen-
ters were randomized 1:1:1 to 1 of the 3 treatment
arms: intravitreal ranibizumab (0.5mg) injection + sham
laser, adjunctive administration of intravitreal ranibizumab
(0.5mg) injection + active laser, or laser treatment + sham
injections for 12 months.
Ranibizumab alone and combined with laser treatment
was superior to laser monotherapy in improving the mean4 Journal of Ophthalmology
average change in the BCVA letter score from baseline to
months 1 through 12 (+6.1 and +5.9 versus −0.8; both P<
0.0001). At month 12, a signiﬁcantly greater proportion of
patients had a BCVA letter score of 15 and a BCVA letter
score level >73 (20/40 Snellen equivalent) with ranibizumab
(22.6% and 53%, resp.) and ranibizumab + laser treatment
(22.9% and 44.9%) versus laser treatment alone (8.2% and
23.6%). The mean CFT was signiﬁcantly reduced from
baseline with ranibizumab (−118.7µm) and ranibizumab
+ laser (−128.3µm) versus the laser alone (−61.3µm; both
P<0.001). Patients received ∼7 (mean) ranibizumab/sham
injections over 12 months.
3.3. READ-2 Study [59, 60]. The Ranibizumab for Edema of
the MAcula in Diabetes-2 (READ-2) study was designed to
compare ranibizumab with focal/grid laser treatment or a
combination of both in DME patients. A total of 126 patients
with DME were randomized 1:1:1 to receive 0.5mg of
ranibizumab at baseline and months 1, 3, and 5 (group 1, 42
patients),focal/gridlaserphotocoagulationatbaselineandat
month 3 if needed (group 2, 42 patients), or a combination
of 0.5 mg of ranibizumab and focal/grid laser treatment at
baselineandmonth3(group3,42patients).Month6wasthe
primary end point of this study. Starting at month 6, if the
retreatment criteria were met, all subjects could be treated
with ranibizumab. At month 6, the mean gain in the BCVA
was signiﬁcantly greater in group 1 (+7.24 letters, P<0.01,
analysis of variance) compared with group 2 (+0.43 letters),
andgroup3(+3.80letters)wasnotstatisticallydiﬀerentfrom
group 1 or 2. For patients with data available at 6 months,
improvement of 3 lines or more occurred in 8 of 37 (22%)
patients in group 1 compared with 0 of 38 (0%) in group 2
(P<0.002, Fisher exact test) and 3 of 40 (8%) in group 3.
The excess foveal thickness was reduced by 50%, 33%, and
45% in groups 1, 2, and 3, respectively. After the primary
end point at month 6, most patients in all three groups were
treated only with ranibizumab, and the mean number of
injections was 5.3, 4.4, and 2.9 during the 18-month follow-
up period in groups 1, 2, and 3, respectively. For the 33
patients in group 1, 34 patients in group 2, and 34 patients
in group 3 who remained in the study for 24 months, the
mean improvement in the BCVA was 7.4, 0.5, and 3.8 letters
at the 6-month primary end point, compared with 7.7, 5.1,
and 6.8 letters at month 24, and the percentage of patients
who gained 3 lines or more of the BCVA was 21%, 0%,
and 6% at month 6, compared with 24%, 18%, and 26% at
month 24. The percentage of patients with a 20/40 or better
Snellen equivalent at month 24 was 45% in group 1, 44%
in group 2, and 35% in group 3. The mean CFT, deﬁned
as the center subﬁeld thickness, at month 24 was 340µm,
286µm, and 258µm for groups 1, 2, and 3, respectively, and
the percentage of patients with center subﬁeld thickness of
250µm or less was 36%, 47%, and 68%, respectively.
Intraocular injections of ranibizumab provided beneﬁt
for patients with DME for at least 2 years, and when
combined with focal or grid laser treatments, the amount
of residual edema was reduced, as were the frequency of
injections needed to control the edema.
3.4. The DA VINCI Study [18]. The primary purpose of
the DME and VEGF Trap-Eye: Investigation of Clini-
cal Impact (DA VINCI) Study (multicenter, randomized,
double-masked, phase 2 clinical trial) was to determine
whether diﬀerent doses and dosing regimens of intravitreal
VEGF Trap-Eye are superior to standard macular laser
treatment over a 24-week study in eyes with DME.
VEGF Trap-Eye is a 115-kDa recombinant fusion protein
consisting of the VEGF-binding domains of human VEGF
receptors 1 and 2 fused to the Fc domain of human
immunoglobulin-G1. Animal studies have demonstrated
that intravitreal VEGF Trap-Eye has theoretic advantages
over ranibizumab and bevacizumab, including a longer half-
life in the eye and a higher binding aﬃnity to VEGF-A. In
addition, the fusion protein binds placental growth factors
1 and 2, which have been shown to contribute to excessive
vascular permeability and retinal neovascularization.
A total of 221 patients were assigned to 1 of 5 treatment
regimens: 0.5mg VEGF Trap-Eye every 4 weeks; 2 mg VEGF
Trap-Eye every 4 weeks; 2mg VEGF Trap-Eye for 3 initial
monthly doses and then every 8 weeks; 2mg VEGF Trap-
Eye for 3 initial monthly doses and then on a PRN basis;
or macular laser photocoagulation. Patients in the 4 VEGF
Trap-Eye groups experienced mean visual acuity beneﬁts
ranging from +8.5 to +11.4 ETDRS letters versus only +2.5
letters in the laser group (P<0.0085 for each VEGF Trap-
Eye group versus laser). Gains from baseline of +0, +10,
and +15 letters were seen in up to 93%, 64%, and 34% of
VEGF Trap-Eye groups versus up to 68%, 32%, and 21%
in the laser group, respectively. The mean reductions in the
CFT in the 4 VEGF Trap-Eye groups ranged from −127.3 to
−194.5µm compared with only −67.9µm in the laser group
(P<0.0066 for each VEGF Trap-Eye group versus laser).
VEGF Trap-Eye was generally well tolerated. The ocular
adverse events in patients treated with VEGF Trap-Eye were
generally consistent with those seen with other intravitreal
anti-VEGF agents.
This study demonstrated that the diﬀerent doses (0.5
or 2mg) and dosing regimens (given every 4 weeks, every
8 weeks, or on a PRN basis) of VEGF Trap-Eye were all
individually superior to laser therapy and resulted in statis-
tically signiﬁcant increases in visual acuity and reductions in
retinal thickness at week 24. The reports mentioned above
may lead to a shift in treatment paradigm for DME, from
laser photocoagulation, to newer approaches using either
ranibizumab or aﬂibercept.
4. Evaluationsof the Outcomes of Anti-VEGF
Therapy for Age-Related Macular
Degeneration
There have been several well-publicized prospective, ran-
domized studies that have demonstrated the eﬃcacy of
intravitreal injection of anti-VEGF drugs (ranibizumab,
pegaptanib, and aﬂibercept; VEGF Trap-Eye) for patients
with age-related macular degeneration (AMD).
The MARINA (Minimally classic/occult trial of the
Anti-VEGF antibody Ranibizumab In the treatment ofJournal of Ophthalmology 5
Neovascular Age-related Macular Degeneration) study [1]
demonstratedtheintravitrealadministrationofranibizumab
for 2 years to prevent vision loss while improving the mean
visual acuity with low rates of serious adverse events, in
patients with minimally classic or occult choroidal neovas-
cularization secondary to age-related macular degeneration.
The ANCHOR (ANti-VEGF antibody for the treatment
of predominantly classic CHORoidal neovascularization in
age-related macular degeneration) study [2] demonstrated
that ranibizumab provided greater clinical beneﬁt after 2
years than verteporﬁn PDT in patients with age-related
maculardegenerationwithnew-onset,predominantlyclassic
CNV.
The PIER (Phase IIIb, multicenter, randomized, double-
masked, sham Injection-controlled study of the Eﬃcacy and
safety of Ranibizumab in subjects with subfoveal CNV with
or without classic CNV secondary to age-related macular
degeneration) study [3, 4] demonstrated that ranibizumab
administered monthly for three months and then quarterly
provided VA beneﬁts to patients with neovascular AMD
and was well tolerated. However, the observations from
the MARINA and ANCHOR trials suggest that the PIER
regimen of dosing every three months after three monthly
doses provides less beneﬁt in terms of VA on average
than continued monthly dosing. Monthly dosing may be
necessary in some patients to achieve maximal treatment
beneﬁt from ranibizumab.
The PrONTO (Prospective Optical coherence tomogra-
phy imaging of patients with Neovascular age-related macu-
lar degeneration Treatment with intraOcular ranibizumab)
study [28, 29] used an Optical Coherence Tomography
(OCT)-guided variable dosing regimen with intravitreal
ranibizumab. During the ﬁrst year, retreatment with rani-
bizumabwasperfo rmedateac hmo nthlyvisitifan ycrit erio n
was fulﬁlled such as an increase in OCT-CFT of at least
100µm or a loss of 5 letters or more. During the second
year, the retreatment criteria were amended to include
retreatment if any qualitative increase in the amount of ﬂuid
was detected using OCT. This study demonstrated that at
month 24, the mean VA improved by 11.1 letters and the
CFT decreased by 212µm. The VA improved by 15 letters
or more in 43% of patients. These VA and OCT outcomes
were achieved with an average of 9.9 injections over 24
months. As-needed (PRN), OCT-guided variable dosing
with intravitreal ranibizumab resulted in VA outcomes
comparable to the outcomes from the phase III clinical
studies (monthly injection), but fewer intravitreal injections
were required.
The V.I.S.I.O.N (VEGF Inhibition Study InO cular Neo-
vascularization) study [7] demonstrated that in the group
given pegaptanib at 0.3mg, 70% of patients lost fewer than
15 letters of visual acuity, as compared with 55% among
the controls (P<0.001). Pegaptanib appears to be an
eﬀective therapy for AMD. However, it does not lead to any
improvement in the mean visual acuity.
The LEVEL (EvaLuation of Eﬃcacy and Safety in Main-
taining Visual Acuity with SEquential Treatment of Neovas-
cuLar AMD) study [8] assessed the eﬃcacy of pegaptanib
as maintenance therapy in AMD patients who experienced
a clinical improvement in disease following an induction
phase. The induction maintenance using nonselective, fol-
lowed by selective VEGF inhibitors should be considered
for the treatment of AMD. Such an approach has special
relevanceforpatientswithcardiovascularcomorbiditieswho
require anti-VEGF drugs to manage their AMD.
The Comparison of Age-Related Macular Degeneration
Treatments Trials (CATT) research group [9] demonstrated
that at 1 year, bevacizumab and ranibizumab had equivalent
eﬀects on visual acuity when administered according to
the same schedule. Bevacizumab administered monthly was
equivalent to ranibizumab administered monthly, with 8.0
and 8.5 letters gained, respectively.
The CLEAR-IT (CLinical Evaluation of Anti-angiogene-
sis in the Retina Intravitreal Trial) study [10] demonstrated
that PRN dosing of VEGF Trap-Eye after 12 weeks of
monthly or quarterly ﬁxed dosing maintained clinically and
statistically signiﬁcant improvements in vision and retinal
thickness until at least week 52 in patients with neovascular
AMD, with a low frequency of reinjection. VEGF Trap-Eye
was generally well tolerated, with a safety proﬁle similar to
that reported with other intravitreally administered anti-
VEGF agents.
5. Neovascular Glaucoma
The normal trabecular meshwork consists of trabecular
spaces and trabecular cells covering trabecular beams, and
it contains no vascular structures. Neovascular glaucoma is
a severe consequence of ocular ischemic diseases, such as
diabetic retinopathy and central retinal vein occlusion. The
elevated intraocular pressure (IOP) is considered to result
from an increased permeability of the newly formed vessels
[61], angle closure by the peripheral anterior synechia,
and intertrabecular neovascular tissue [62, 63]. An ultra-
structural study showed that the neovascular tissue in the
intertrabecular spaces may be one of the factors responsible
for the IOP elevation. The layers of vascular endothelial
cells have junctional complexes and fenestrations [63]. The
intravitreal injection of bevacizumab was reported to be
eﬀective for inducing the regression of new vessels, although
its eﬀect seems to be temporary [24–32, 35–38]. In an
animal˜study, bevacizumab penetrated quickly into the
iris, anterior chamber angle and ciliary body after IVB.
This ﬁnding supports the clinically observed rapid eﬀect
of bevacizumab in the treatment of iris neovascularization
[64]. This injection may provide us with suﬃcient time
to treat these patients with retinal photocoagulation. In
addition, it may also be used as an adjunctive therapy
for a mitomycin C (MMC) trabeculectomy in order to
t r e a tN V G .T h eu s eo fp r e o p e r a t i v eI V Bm a yd e c r e a s e
postoperative hyphema, however the beneﬁcial eﬀects of IVB
are controversial for surgical outcomes over longer periods
[37, 38].
Ishibashi et al. [65] performed anterior segment angiog-
raphywithbothﬂuorescein(FA)andindocyaninegreen(IA)
using a Heidelberg retina angiograph 2 on the patients with
NVG. FA showed intensive leakage of the dye from newly6 Journal of Ophthalmology
formed vessels, although IA revealed the vessel structures
clearly without dye leakage. In both iris and angle angiogra-
phy, dye leakage with FA was decreased after IVB compared
with that before treatment. The vascular structures in the iris
and angle observed with IA, however, did not change after
IVB, although the newly formed vessels in the tissues seemed
to vanish based on slit-lamp examinations.
Kubota et al. [66] showed that CD34 positive vascular
endothelial cells formed capillary-like structures in the tra-
becular meshwork of NVG after an intravitreal injection of
bevacizumab.Althoughtheslitlampandgonioscopicexami-
nationsrevealedaregressionofthenewlyformedvesselsafter
the intravitreal injection of bevacizumab, they morphologi-
cally showed that the vascular endothelial cells were present
in the trabecular meshwork. Electron microscopy revealed
that the layer of endothelial cells had junctional complexes.
However, the fenestrations of the vascular endothelial cells
were signiﬁcantly fewer in the trabecular meshwork of ne-
ovascular glaucoma eyes treated with bevacizumab than
thosewithoutthetherapy[66,67].Theintravitrealinjections
of bevacizumab resulted in a decrease in VEGF in the
aqueous humor [68]. Therefore, it is considered that a
decreased VEGF concentration in the aqueous humor causes
a reduction of the fenestrations of the vascular endothelial
cells in the trabecular tissue of neovascular glaucoma after
an intravitreal injection of bevacizumab. These morpho-
logical alterations may play an important role in the clin-
ical eﬀects of intravitreal bevacizumab for neovascular
glaucoma.
Although the eﬀect of bevacizumab seems temporary,
previous clinical reports suggested the potential for intrav-
itreal bevacizumab as a treatment option for neovascular
glaucoma [24–32]. Adjuvant bevacizumab for neovascular
glaucoma may prevent further PAS formation, and it is
likely to open up a therapeutic window for a panretinal
photocoagulation and trabeculectomy. Johnson et al. [61]
reported that one of the factors aﬀecting the IOP elevation
is the concentration of the serum protein in the aqueous
humor. It has been suggested that one possible mechanism
underlying the IOP elevation is the increased permeability
of the newly formed vessels. The fenestrations of the
newly formed vessels are thus considered to have a close
relationshiptosuchpermeability.Bevacizumabmayinducea
reduction of the capillary structures and fenestrations of the
vascular endothelium in the trabecular tissue, and therefore,
has an IOP lowering eﬀect and a reduced risk of hemorrhage
during trabeculectomy.
It was still unclear from these studies whether beva-
cizumab temporally induces a reduction of the perfusion
of the newly formed vessels, or a disappearance of the
newly formed vessels in the trabecular meshwork. Another
previous study [67] suggested that the number and perfu-
sion of the newly formed vessels were reduced. However,
to fully elucidate how a reduction of the newly formed
vessels occurred in the trabecular meshwork of neovascular
glaucoma after intravitreal bevacizumab injection, further
studies are needed.
6. ProliferativeDiabeticRetinopathy
VEGF is a key molecule involved in the development of reti-
nal neovascularization [69–71]. Studies have demonstrated
not only a correlation of the VEGF levels with the severity
of proliferative diabetic retinopathy (PDR), but also a re-
duction in the levels after successful laser treatment of PDR
[48]. Ischemia in the retina due to microvascular occlusion
induces the release of VEGF into the vitreous cavity; highly
concentrated VEGF in the ocular ﬂuid leads to the growth
of new vessels [48]. VEGF also increases the permeability
of capillary vessels and contributes to diabetic macular
edema [72, 73]. Retinal ﬁbrovascular membranes, including
neovascularization, represent an important risk factor for
severe vision loss in patients with diabetic retinopathy. An
ultrastructural study of the ﬁbrovascular membranes in a
patient with proliferative diabetic retinopathy demonstrated
that the newly formed vessels frequently showed endothelial
fenestrations. Occasionally, the tight junctions between
endothelial cells appeared altered [74].
IVB results in a substantial decrease in VEGF in the
aqueous humor [68]. Bleeding from the retinal vessels or
new vessels during a standard vitrectomy after IVB has
been reported to occur signiﬁcantly less frequently than that
observedduringastandardvitrectomywithoutbevacizumab
therapy [33, 39–41]. IVB has also been reported to be
eﬀective for inducing the regression of new vessels in PDR
[19, 20, 33, 34]. An angiographic study demonstrated that
the leakage was noted to diminish as early as 24 hours
after IVB [19]. IVB also resulted in marked regression of
neovascularization and rapid resolution of vitreous hem-
orrhage [22]. A randomized, placebo-controlled clinical
trial revealed the eﬃcacy of IVB in reducing the rate of
early postoperative vitreous hemorrhage after vitrectomy in
diabetic patients [75]. The balance between connective tissue
growth factor and vascular endothelial growth factor may be
thestrongestpredictorofthedegreeofﬁbrosis;ashifttoward
connective tissue growth factor can underlie the aggravation
of ﬁbrosis after IVB [76]. Moradian et al. [77]r e p o r t e d
exacerbation and subsequent contracture of ﬁbrous tissue
leading to tractional retinal detachment (TRD) in 2 patients
who received IVB for active aggressive PDR. In a report by
Arevalo et al. [78], TRD occurred in 11 eyes (5.2%) among
211 intravitreal injections in patients with severe PDR. A
longer interval between IVB and vitrectomy was among the
main risk factors for the development or progression of
TRD.
Histological studies have shown vascular endothelial
cells to still be present in the FVMs following IVB [67,
79, 80]. No apparent fenestration was observed in newly
formed vessels from the FVMs. A histological study showed
apoptotic vascular endothelial cells and overexpression of
smooth muscle actin in the FVMs after IVB [67]. The
authors of that study concluded that IVB may induce
changes in immature, newly formed vessels of PDR, leading
to endothelial apoptosis with vascular regression, while
inducing normalization of premature vessels by increasing
the pericyte coverage and reducing vessel fenestration.
Another study suggested that retinal neovascularizationJournal of Ophthalmology 7
is markedly reduced on approximately day 10 after IVB
injection, whereas contractile elements are not yet abundant
[80]. Therefore, IVB may temporally reduce the blood ﬂow
of the newly formed vessels, however, it did not induce
the complete regression of the vascular endothelium of the
FVMs. Therefore, the blood ﬂow of the newly formed vessels
may be easily reperfused when the eﬀect of bevacizumab
diminishes.
7.Retinopathy of Prematurity
An overexpression of VEGF appears to be important in the
pathogenesis of retinopathy of prematurity (ROP). Laser
photocoagulation of the avascular retina reduces the risk
of severe visual loss, presumably by decreasing VEGF pro-
duction, but causes loss of peripheral retinal function. Some
patients progress to retinal detachment despite laser or
cryotherapy. The functional outcomes are still not satisfying
instage4Bor5ROP,evenaftervitrectomyorscleralbuckling
[81, 82]. There has, therefore, been considerable interest
in the potential application of anti-VEGF agents, such as
bevacizumab, as primary treatment or as an adjunct to
photocoagulation [83–89]. Because VEGF is highly elevated
in advanced ROP and has been found to play a central role
as the driving force for neovascularization [90, 91], blocking
VEGF with anti-VEGF agents seems to be a reasonable
approach. Bevacizumab seems to work best in stage 3
ROP. The majority of the treated eyes did not progress
to stage 4 ROP even without additional injection or laser
therapy. However, some patients received laser treatment
if positive symptoms or neovascularization persisted or
worsened [85, 92–95]. The purpose of bevacizumab use in
stage 4 or 5 patients is to reduce the plus sign to help reduce
hemorrhage during the subsequent vitrectomy [88, 93, 96].
Some authors reported cases of resolution of stage 4A ROP
after bevacizumab injection [86, 93]. However, caution is
necessary when bevacizumab is used in ROP with retinal
detachment. While angiogenesis is inhibited, the ﬁbrotic
components of ROP may accelerate and retinal detachment
might worsen [97].
Potential local and systemic complications of intravitreal
injection of anti-VEGF medications are one of the major
concerns especially for infants with a very small eye size and
small body mass with rapidly developing tissue [89]. VEGF
plays a number of critical roles in the developing retina as a
survival factor for retinal neurons [98] and in maintaining
the health of the retinal pigment epithelium [99]. It also
inﬂuences neuronal growth and diﬀerentiation because of its
neurotrophic eﬀects [100, 101] and has a critical role as a
neuroprotectantinthecentralnervoussystemintheadaptive
response to ischemia [102]. The only histopathologic study
evaluating neonate ocular specimens 20 weeks after IVB
showed that bevacizumab was well tolerated without any
signs of toxic eﬀects including inﬂammation, degeneration,
or necrosis [103]. The beneﬁcial eﬀects and advantages of
bevacizumab for ROP that have been reported in the limited
literature to date, indicate that further randomized control
trials are warranted.
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